Observational study for patients at risk of chronic graft-versus-host disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather data from individuals who have recently undergone an allogenic stem cell transplant and are at risk for developing chronic graft-versus-host disease (cGVHD). Participants will be monitored for 90 to 180 days post-transplant to assess their health and any signs of cGVHD. The study is non-interventional, meaning no additional treatments will be administered as part of the study. Data collected will help improve understanding and management of cGVHD in transplant patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years inclusive at the time of signing the ICF
* Allogeneic SCT 90 to 180 days prior to enrollment
* Able to comprehend and willing to provide informed consent
* Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel

Exclusion Criteria:

* There are no exclusion criteria for this study

Where it's running

• University of Alabama Birmingham
  Birmingham, Alabama, United States Recruiting
• Mayo Clinic Arizona
  Phoenix, Arizona, United States Recruiting
• City of Hope
  Duarte, California, United States Recruiting
• USC Norris Comprehensive Cancer Center
  Los Angeles, California, United States Recruiting
• University of Colorado
  Aurora, Colorado, United States Recruiting
• Colorado Blood Cancer Institute/Presbyterian St. Luke's
  Denver, Colorado, United States Recruiting

Study contacts

• Study coordinator: Incyte Corporation Call Center (US)
• Email: medinfo@incyte.com
• Phone: 1.855.463.3463

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Belumosudil vs. Ruxolitinib for hepatic cGVHD after HSCT

  This trial tests whether belumosudil or ruxolitinib works better for hepatic chronic GVHD after a stem cell transplant in people 12 and older.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07794514

• GT729 universal cell injection for refractory or relapsed chronic graft-versus-host disease

  This trial will try GT729 universal cell injections in adults whose chronic graft-versus-host disease has not responded to at least two prior systemic treatments after an allogeneic stem cell transplant.

  Recruiting Early Phase 1 Grit Biotechnology · Tianjin, Tianjin Municipality · NCT07253259

• BPC2001 to prevent acute graft-versus-host disease after haploidentical stem cell transplant

  This trial tests whether six weekly doses of BPC2001 given with standard care can prevent acute graft-versus-host disease in adults having haploidentical stem cell transplants.

  Recruiting at 2 sites Phase 2 BioPhoenix Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07246031

• Donor-derived regulatory T cell infusion with interleukin-2 for refractory chronic GVHD

  This will try infusing donor-derived regulatory T cells together with low-dose recombinant interleukin-2 in adults with steroid-refractory or steroid-dependent chronic graft-versus-host disease.

  Recruiting Early Phase 1 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT06920199

• Combination treatment for chronic Graft-versus-Host Disease

  This study is testing a new combination treatment with Axatilimab and light therapy to see if it helps people with chronic Graft-versus-Host Disease who haven't responded well to other treatments.

  Recruiting at 3 sites Phase 2 University of Miami · San Francisco, California and 2 other locations · NCT06663722

• Using Iguratimod to treat chronic graft-versus-host disease

  This study is testing if Iguratimod, a medication usually for rheumatoid arthritis, can help people with chronic graft-versus-host disease feel better and improve their lung function.

  Recruiting Phase 1/2 Xuzhou Medical University · Xuzhou, Jiangsu · NCT06244628

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.